MOTS-C and 5-Amino-1MQ are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Same neighbourhood, different chemistry
It is easy to see why these two get mentioned in the same breath: both are studied for metabolic effects, both intersect with NAD+ and mitochondrial energy biology, and both turn up in the same "metabolic" research stacks. But they are not the same kind of thing. MOTS-C is a 16-amino acid peptide encoded by the mitochondrial genome. 5-Amino-1MQ is a small synthetic molecule — a methylquinolinium — not a peptide at all. That distinction in modality drives almost every other difference between them: how they are targeted, how they behave in solution, how long they persist, and where each one has been studied. Below we put the two side by side, then take each in turn.
| MOTS-C | 5-Amino-1MQ | |
|---|---|---|
| Class / type | Mitochondrial-derived peptide (16 aa) | Small-molecule NNMT inhibitor |
| Primary target | AMPK pathway (activator) | NNMT enzyme (inhibitor) |
| Structure / MW | 16-residue peptide, mitochondrial 12S rRNA sORF | 5-amino-1-methylquinolinium · ~174.65 Da |
| Half-life / duration | Short (delivery-limited, low bioavailability) | ~24 hours (reported) |
| Main research focus | Exercise mimetic, ageing/healthspan, glucose metabolism | Adipose tissue, fat mass, NAD+/methylation balance |
| Regulatory status | Investigational; WADA-prohibited (AMPK activators) | Investigational; unregulated research compound |
MOTS-C: the mitochondrial peptide that activates AMPK
MOTS-C (Mitochondrial ORF of 12S rRNA Type-C) is a genuine curiosity of cell biology. Discovered in 2015 by Lee and colleagues in Cell Metabolism, it is one of a newly characterised class of mitochondrial-derived peptides — short bioactive sequences encoded not by the nuclear genome but by the mitochondrial genome itself. It behaves like an endocrine signal, which is why it is often called a "mitokine": circulating MOTS-C rises with exercise and falls with age.
Mechanistically, MOTS-C works upstream. Its principal action is activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. Through AMPK it promotes GLUT4-mediated glucose uptake in skeletal muscle, increases fatty acid oxidation and supports mitochondrial biogenesis. Because acute exercise induces MOTS-C and the peptide reproduces several downstream features of exertion, much of the research frames it as an exercise mimetic and a subject in longevity and metabolic biology. The catch for anyone working with it is practical: as a peptide it faces delivery challenges — low bioavailability and a short half-life — which is exactly why it is handled as a research reagent. Our full MOTS-C knowledgebase profile covers the discovery and preclinical literature in more depth, and researchers sourcing material can buy MOTS-C UK in three strengths.
5-Amino-1MQ: the small-molecule NNMT inhibitor
5-Amino-1MQ approaches metabolism from the other direction — and it is worth being precise about what it is. It is a small molecule, 5-amino-1-methylquinolinium, with a molecular weight around 174.65 Da; it is not a peptide. Its target is the enzyme nicotinamide N-methyltransferase (NNMT), which it competitively inhibits at the active site.
Why NNMT matters is a story about two currencies. NNMT methylates nicotinamide, and in doing so it consumes both the NAD+ precursor pool (nicotinamide) and the universal methyl donor S-adenosylmethionine (SAM). NNMT activity is markedly elevated in adipose tissue with ageing and obesity, so it acts as a metabolic bottleneck that quietly drains tissue NAD+ and methylation capacity. Blocking it with 5-Amino-1MQ lets both pools recover. In preclinical obesity models this has been associated with reduced fat mass and improved glucose tolerance — effects attributed to restored NAD+ and methylation balance in adipocytes rather than any direct lipolytic or appetite-suppressing action. That places it in NAD+-pathway research as a "spare the precursor" strategy, complementary to direct NAD+ or precursor approaches such as NMN and NR. The 5-Amino-1MQ knowledgebase profile sets out the NNMT literature, and you can buy 5-Amino-1MQ UK for laboratory work.
What the differences mean in a research context
Read the table across and the contrast is structural, not merely a matter of degree. MOTS-C is a peptide agonist that switches something on — AMPK — high in the signalling cascade, so its effects fan out across glucose handling, fat oxidation and mitochondrial biogenesis. 5-Amino-1MQ is a small-molecule inhibitor that takes something away — NNMT activity — relieving a specific enzymatic bottleneck so that NAD+ and methyl-donor pools can rebuild. One adds a signal; the other removes a drain.
That difference in modality has hands-on consequences. As a small molecule, 5-Amino-1MQ is generally more stable and has a longer reported persistence (a half-life on the order of a day), whereas MOTS-C carries the handling constraints typical of peptides — the short half-life and bioavailability limits that have shaped its preclinical development. Their evidence bases also point in slightly different directions: MOTS-C is anchored in exercise physiology, ageing and skeletal-muscle glucose metabolism, while 5-Amino-1MQ is anchored in adipose-tissue and NNMT biology.
Importantly, this is not really an either/or. Because they act at different nodes of the same energy axis — AMPK signalling on one side, the NNMT/NAD+ bottleneck on the other — the two are studied together as often as they are compared. They co-occur in the Mito Stack alongside NAD+ itself, precisely because upstream signalling, direct substrate provision and bottleneck relief are three distinct levers on the same system. For research design, the honest framing is that "MOTS-C vs 5-Amino-1MQ" is less a contest than a choice of which mechanism you want to interrogate.
The bottom line
MOTS-C is a mitochondrial-derived peptide that activates AMPK and is studied as an exercise-mimetic metabolic regulator. 5-Amino-1MQ is a small-molecule NNMT inhibitor studied for adipocyte metabolism and fat research. Same neighbourhood, different chemistry, different levers — and, in many stacks, complementary rather than rival. For research-grade material with a COA and ≥99% purity, see our dedicated pages to buy MOTS-C UK and to buy 5-Amino-1MQ UK.